Search Results for: Other News to Note
-
Other News To Note
Under the terms, Hewlett Packard will continue to manufacture confocal laser scanners that will be sold by Affymetrix as part of its GeneChip system...The GeneChip system acquires, analyzes and manages complex genetic information in order to improve the diagnosis, monitoring and treatment of disease. * Cardiovascular Diagnostics Inc. (CVDI), of Raleigh, N.C., and Chiron Corp., of Emeryville, Calif., signed a $6 million global distribution agreement for certain CVDI diagnostic coagulation tests -
Other News To Note
The companies were already collaborating on other projects. * Genzyme Corp., of Cambridge, Mass., and BASF AG, of Ludwigshafen, Germany, signed a five-year exclusive agreement to jointly promote and market Genzyme's Thyrogen recombinant thyroid stimulating hormone in the U.S., following regulatory approval...Lexicon also gets rights to use Cre-lox to practice gene trapping in mouse embryonic stem cells -
Other News To Note
Both companies are majority-owned subsidiaries of Lexington, Mass.-based Interneuron Pharmaceuticals Inc. (See BioWorld Today, Nov. 7, 1997, p. 1.) * Nexell Therapeutics Inc., of Wilmington, Del., initiated a 30-patient Phase I/II clinical study to evaluate the potential value of using the Isolex 300i Stem Cell Selection System to treat Chronic Granulamatous Disease, a hereditary disease involving a genetic defect in the ability of certain white blood cells to kill bacteria -
Other News To Note
The company licensed worldwide marketing rights to the drug to Zeneca Group plc, of London, in a deal worth $25 million. (See BioWorld Today, April 1, 1998, p. 1.)* Gensia Sicor Inc., of Irvine, Calif., completed its oncology product manufacturing facility where Gensia Sicor Pharmaceuticals, a wholly owned subsidiary of Gensia Sicor, will produce injectable oncology products. * Genvec Inc., of Rockville, Md., licensed rights for all gene therapy applications of the tumor necrosis factor alpha -
Other News To Note
The goal is to combine technology designed by Osiris involving a patient's own mesenchymal stem cells with a treatment approach pioneered at JHU to induce specific immunity against certain white blood cells (T cells) that play a pivotal role in the disease. * Pathogenesis Corp., of Seattle, received a $100,000 Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases -
Other News To Note
Clinical studies have shown that peripheral blood stem cells can achieve effective long-term hematopoietic reconstitution similar to bone marrow-derived stem cells. * Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., presented initial results of Phase I/II trials of its lead HIV product, PRO 542 -
Other News To Note
The product is a stabilized foam formulation of betamethasone 17-alpha-valerate, used to treat all steroid-responsive dermatoses, including psoriasis. (See BioWorld Today, Jan. 6, 1997, p. 1.) * UroGenesys Inc., of Santa Monica, Calif., obtained exclusive commercial rights to a gene linked to prostate cancer...Called prostate stem cell antigen, the gene produces a protein found more prevalently on the surface of prostate cancer cells than normal prostate cells -
Other News To Note
It will be used with the company's Ceprate SC Stem Cell Concentration System to reduce the number of B cells in mobilized peripheral blood used for autologous hematopoietic transplantation in patients with relapsed non-Hodgkin's lymphoma...Late last year, Atrix, which develops, manufactures and markets products based on its Atrigel biodegradable polymeric technology, raised $50 million in a private placement. (See BioWorld Today, Nov. 25, 1997, p. 1.) * CellPro Inc., of Seattle, said it received -
Other News To Note
to manufacture LXR's investigational heart protectant products, HK-Cardiosol and CP-Cardiosol. * Origen Therapeutics Inc., of South San Francisco, obtained an exclusive license from North Carolina State University for applications of avian embryonic stem cell technologies that allow the precise genetic modification of all avian species, including commercial poultry...patents pertaining to its product Taxol, a breast cancer therapy -
Third Quarter Epogen Charge Cuts Amgen's '97 Profit
To support that pipeline, Amgen spent $630.8 million (26 percent of revenues) on research and development, up from $528.3 million (24 percent of revenues) in 1996...Stemgen, a stem-cell factor for use in cancer patients undergoing chemotherapy, is on track for FDA approval and commercial launch this year, with an MGDF launch possible in 1999 or 2000, according to the UBS analysts...Amgen's pipeline continues to under perform," he wrote in an earnings note -
Other News To Note
The multiyear deal gives ZymoGenetics a subscription to the database that corresponds to a library of mutant mouse embryonic stem cell clones...MSS said it is developing tests for genetic susceptibility to osteoporosis, heart disease and diabetic retinopathy, and expects to announce other tests this year -
Other News To Note
The gene therapy involves removal of patients immune and stem cells, treatment with Enzo's StealthVector to make them HIV resistant, and reinfusion to generate more HIV-resistant cells. * Liposome Co., of Princeton, N.J., entered an agreement with American Home Products Corp., of Madison, N.J., to market Liposome's Abelcet in Denmark, Finland, Iceland, Norway and Sweden -
Other News To Note
The drug is also in an ongoing multiple target Phase I trial. * Procept Inc., of Cambridge, Mass., has begun analysis of a completed second Phase I trial of Pro 2000 Gel, an intravaginally delivered gel designed to prevent HIV-1 infection and other sexually transmitted diseases...According to the company, 1,500 people are severely burned each year, but 30,000 to 40,000 patients each year seek medical treatment for partial-thickness burns. * Stem Cell Therapuetics L.L.C., of King of Prussia, Pa -
Other News To Note
RiboGene will use its genomics expertise to identify targets for therapeutic compounds developed by ArQule. * CellPro Inc., of Seattle, applied to the FDA to expand the label of its Ceprate SC Stem Cell Concentration System to include selection of peripheral blood stem cells -
Other News To Note
Two of the company's products use encapsulated cell implants to deliver growth factors and neural stem cells, replacing neural tissue damaged by disease or injury. * CytRx Corp., of Atlanta, received a grant from the FDA's division of orphan drug development to support the company's upcoming study of Flocor, used to treat sickle-cell patients undergoing acute vaso-occlusive crises -
Other News To Note
One grant from the National Heart, Lung and Blood Institute will fund studies into therapeutic uses of stem cells derived from umbilical cord blood and the other will explore a suicide gene therapy for AIDS in which patients' healthy cells would die when infected with HIV, preventing the virus from replicating. * Biogen Inc., of Cambridge, Mass., said it will repurchase 2.5 million shares of its common stock over the next two years. * Medicines Co., of Cambridge, Mass., said Phase II results -
Other News To Note
Aastrom's cell production system will be used to produce ex vivo stem cells from a small amount of umbilical cord blood for transplant to 30 adults and children for whom no matched bone marrow donors were found. * Bio-Technology General Corp., of Iselin, N.J., said a Phase I trial of a deep vein thrombosis (DVT) diagnostic, employing the company's genetically engineered fibrin binding domain (FBD) peptide, was begun by Draxis Health Inc., of Mississauga, Ontario, which licensed the peptide -
Other News To Note
Geron's research on primordial stem cells, which are formed early in human embryonic development, will focus on analyzing genes linked to cell differentiation -
Other News To Note
Lexicon Genetics Inc., of The Woodlands, Texas, delivered to the Merck Genome Research Institute Inc., of West Point, Pa., the first 10 mutant mouse models of diseases for use in studying the functions of specific genes linked to the disorders...The mice created from the cell clones are used to determine the functions of the gene under study -
Other News To Note
The acquisition is expected to allow CytoTherapeutics to accelerate the development of a new category of human neural stem cell product candidates and enhance the development of CytoTherapeutics' lead product for chronic pain
Category
Current Filters
- xstem cells
Related Keywords
Categories
- x BioWorld Today (1190)
- x BioWorld International (249)
- x BioWorld Insight (13)
- x Bio Perspectives (10)
- x State of the Industry Report (9)
- x BioWorld Snapshots (1)